Loading...
01/10 01:43
Loading...
Myriad Genetics Inc (MYGN) is set to release its earnings performance on 08/05 04:00:00 in After Hours trading. Consensus forecasts predict a revenue of 202.30M and an earnings per share (EPS) of -0.11 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
The earnings call reveals strong performance with raised revenue and EBITDA guidance, new product launches, and strategic partnerships. Despite some operational challenges, management's optimistic outlook, particularly in prenatal and cancer diagnostics, suggests potential growth. The Q&A highlights market expansion and improved customer workflows, reinforcing positive sentiment. However, unclear responses on ASP assumptions and reimbursement timelines introduce some uncertainty, slightly tempering the overall positive outlook.
The earnings call presents a mixed picture. Financial performance shows improvement, with increased adjusted gross margin and EBITDA. However, the lowered revenue guidance and unresolved issues like SneakPeek and unclear management responses create uncertainties. The strategic focus on oncology and partnerships is promising but lacks immediate impact. Overall, the sentiment is neutral with potential for future growth, but current uncertainties and guidance adjustments balance out the positives.
The earnings call reveals several negative factors: a 3% revenue decline, a significant impact from UnitedHealthcare's policy change on GeneSight, and cash burn issues. Despite some positives like prenatal revenue growth and increased gross margins, the lack of a share repurchase program and unclear management responses in the Q&A section further contribute to uncertainty. The market cap of approximately $2.2 billion suggests moderate sensitivity to these issues, leading to an overall negative sentiment.
Myriad Genetics Inc (MYGN) is scheduled to release its FY2025Q2 earnings report onAug 5, 2025, After Hours(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
Analysts' consensus predicts 202.30M in revenue and an EPS of -0.11 for Myriad Genetics Inc's FY2025Q2.
Intellectia's exclusive AI algorithms forecast a forMyriad Genetics Inc's FY2025Q2 earnings, with a prediction date of Aug 5, 2025. Myriad Genetics Inc
Leverage Intellectia's AI forecast to position trades ahead of theAug 5, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
Each prediction includes a detailed rationale, key indicator forecasts, and scenario probabilities to guide your trades. For a *Beat*, consider buying call options or shares; for a *Miss*, explore puts or hedging strategies. The prediction card provides actionable suggestions, like specific option strikes or hedging tips, tailored to your risk tolerance. Trade smart and turn insights into profits!
